Supernus Pharmaceuticals, Inc.
Clinical trials sponsored by Supernus Pharmaceuticals, Inc., explained in plain language.
A pharmaceutical company specializing in central nervous system (CNS) treatments, including epilepsy and ADHD.
Trade on eToro (ad)Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
-
ADHD drug SPN-812 tested for Long-Term safety in children
Disease control OngoingThis study investigates the long-term safety and effectiveness of SPN-812 (viloxazine) in children and adolescents with ADHD. Participants who completed a prior SPN-812 study can continue taking the medication once daily for up to 72 months. The trial includes children aged 4–17 …
Phase: PHASE3 • Sponsor: Supernus Pharmaceuticals, Inc. • Aim: Disease control
Last updated Jul 17, 2026 00:00 UTC
-
New hope for deadly seizures: experimental drug SAGE-547 tested
Disease control NO_LONGER_AVAILABLEThis study offered SAGE-547, an experimental drug given as a continuous IV infusion, to people aged 6 months and older with super-refractory status epilepticus—a dangerous condition where seizures continue despite standard treatments. The goal was to see if the drug could help co…
Sponsor: Supernus Pharmaceuticals, Inc. • Aim: Disease control
Last updated Jun 26, 2026 16:59 UTC
-
New drug ZULRESSO offers hope for moms with postpartum depression
Symptom relief APPROVED_FOR_MARKETINGThis program provides early access to ZULRESSO (brexanolone) for adult women with postpartum depression before the drug is widely available. Eligible women receive a one-time injection under medical supervision. The goal is to help ease severe depression symptoms quickly.
Sponsor: Supernus Pharmaceuticals, Inc. • Aim: Symptom relief
Last updated Jun 26, 2026 17:07 UTC